Your browser doesn't support javascript.
loading
Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response.
Kuperberg, Maya; Köhler-Forsberg, Ole; Shannon, Alec P; George, Nevita; Greenebaum, Sophie; Bowden, Charles L; Calabrese, Joseph R; Thase, Michael; Shelton, Richard C; McInnis, Melvin; Deckersbach, Thilo; Tohen, Mauricio; Kocsis, James H; Ketter, Terence A; Friedman, Edward S; Iosifescu, Dan V; Ostacher, Michael J; Sylvia, Louisa G; McElroy, Susan L; Nierenberg, Andrew A.
Afiliación
  • Kuperberg M; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: Mayakuperberg@moh.health.gov.il.
  • Köhler-Forsberg O; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Shannon AP; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • George N; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Greenebaum S; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Bowden CL; Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA.
  • Calabrese JR; Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.
  • Thase M; Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
  • Shelton RC; Department of Psychiatry, University of Alabama at Birmingham, Birmingham, AL, USA.
  • McInnis M; Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
  • Deckersbach T; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Tohen M; Department of Psychiatry, University of New Mexico Health Science Center, Albuquerque, NM, USA.
  • Kocsis JH; Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA.
  • Ketter TA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
  • Friedman ES; Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Iosifescu DV; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
  • Ostacher MJ; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
  • Sylvia LG; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • McElroy SL; Department of Psychiatry and Behavioral Neuroscience, OH and Lindner Center of HOPE, University of Cincinnati College of Medicine, Cincinnati, Mason, OH, USA.
  • Nierenberg AA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
J Affect Disord ; 300: 41-49, 2022 03 01.
Article en En | MEDLINE | ID: mdl-34952123

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antipsicóticos / Trastorno Bipolar / Enfermedades Cardiovasculares Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Affect Disord Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antipsicóticos / Trastorno Bipolar / Enfermedades Cardiovasculares Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Affect Disord Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos